Related Experiment Video
Updated: Sep 25, 2026
A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics
Published on: June 16, 2013
Soluble markers for the detection of hypoxia under antiangiogenic treatment
1Tumor Biology Center, Albert-Ludwigs-University Hospital, Breisacherstr. 117, D-79106 Freiburg, Germany.
Abstract:
Antiangiogenic therapy is a promising new strategy to inhibit tumor growth and formation of metastases. VEGF (vascular endothelial growth factor) is known to be the most important proangiogenic factor, necessary for the development of new tumor vessels. Specific inhibitors of the VEGF receptor tyrosine kinases, like PTK787/ZK222584 (PTK/ZK), have shown antitumoral and antiangiogenic activity in several animal models. Ongoing early clinical trials with antiangiogenic compounds reveal the need for diagnostic methods to detect their biological activity. Pro-angiogenic growth factors like VEGF and bFGF (basic fibroblast growth factor), soluble variants of proangiogenic receptors like sFLT-1 and sTIE-2, as well as endothelial activation markers like sE-Selectin, can be measured in the serum and plasma of patients by the ELISA technique. They were detected in various malignant diseases to assess their use as surrogate markers in tumor angiogenesis. In different clinical Phase I trials with antiangiogenic compounds, these soluble markers were used to detect dose levels for biological activity. Soluble markers of tumor angiogenesis can be used as prognostic markers in various malignancies like colon cancer or multiple myeloma. Furthermore, they correlated with disease activity, prognosis and imaging techniques for the detection of vascular changes. In clinical Phase I trials with specific inhibitors of the VEGF receptor tyrosine kinases, VEGF serum levels increased in patients treated with higher doses, indicating increasing tumor hypoxia. Taking results from imaging techniques such as dynamic enhanced MRI into account, optimal doses for biological activity could be concluded. New biological treatment techniques will need new diagnostic methods to assess their specific biological activity in patients. Soluble markers and imaging techniques are useful tools for the detection of hypoxia under antiangiogenic treatment. Nevertheless, these techniques are still experimental. Therefore, further clinical evaluation is necessary.
Insights
Antiangiogenic therapy targets tumor growth by inhibiting vascular endothelial growth factor (VEGF). Soluble markers and imaging detect treatment efficacy and tumor hypoxia, aiding optimal dosing in clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Biomarker Discovery
Background:
- Antiangiogenic therapy shows promise in inhibiting tumor growth and metastasis.
- Vascular Endothelial Growth Factor (VEGF) is crucial for tumor vessel development.
- Early clinical trials necessitate diagnostic methods to assess antiangiogenic drug activity.
Purpose of the Study:
- To evaluate soluble markers and imaging techniques for detecting biological activity of antiangiogenic therapies.
- To assess the utility of these markers in determining optimal drug dosage and patient prognosis.
Main Methods:
- Enzyme-Linked Immunosorbent Assay (ELISA) to measure serum/plasma levels of proangiogenic factors (VEGF, bFGF), soluble receptors (sFLT-1, sTIE-2), and endothelial activation markers (sE-Selectin).
- Analysis of these markers in Phase I clinical trials of antiangiogenic compounds.
- Correlation of marker levels with imaging techniques like dynamic enhanced MRI.
Main Results:
- Soluble markers were detected in various malignancies and used to identify biological activity dose levels.
- VEGF serum levels increased with higher doses of VEGF receptor inhibitors, suggesting tumor hypoxia.
- Marker levels correlated with disease activity, prognosis, and imaging findings.
Conclusions:
- Soluble markers and imaging techniques are valuable tools for assessing antiangiogenic treatment efficacy and detecting tumor hypoxia.
- These diagnostic methods aid in determining optimal drug doses for biological activity.
- Further clinical evaluation is required as these techniques are still experimental.
